ncRNA basic information ncRNA ID: MIMAT0002809 ncRNA Database: miRBase ncRNA Name: miR-146b-5p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: TRAF6 ncRNA Pathway: AKT and NF-kappaB pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00853 (APRD00557) Drug Name: Temozolomide Drug Method: In the present study, we successfully generated U87 and U251-TR cells, and found that miR-146b-5p was downregulated in TR cells. Overexpression of miR-146b-5p restored sensitivity of U87/U251-TR cells to TMZ by targeting tumor necrosis factor receptor-associated factor 6 (TRAF6). The levels of TRAF6 were inversely related to miR-146b-5p levels, and overexpression of TRAF6 in miR-146b-5p OE cells enhanced the resistance against TMZ. Moreover, temozolomide-resistant GBM cells had a higher level of phosphorylated protein kinase B (AKT) and P65. Overexpression of miR-146b-5p or TRAF6 knockdown significantly decreased the level of p-AKT and p-p65. Collectively, our data demonstrated that miR-146b-5p, as a tumor suppressor, mediated temozolomide resistance in GBM cells through negatively regulating TRAF6 expression, indicating that miR-146b-5p and its targeted genes would be potential therapeutic targets for glioma therapy. Drug Response: sensitive

Cancer basic information Cancer: glioblastoma Tissue/Cell: cell line (U87-MG,U251-MG)

Other information Title: miR-146b-5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. Journal: Oncol Rep Published: 2017 PubMed ID: 29048680